# A Study Evaluating Implementation Strategies for Cabotegravir (CAB)+ Rilpivirine (RPV) Long-acting (LA) Injectables for Human Immunodeficiency Virus (HIV)-1 Treatment in European Countries

> **NCT04399551** · PHASE3 · COMPLETED · sponsor: **ViiV Healthcare** · enrollment: 437 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** CAB OLI
- **DRUG:** CAB LA
- **DRUG:** RPV OLI
- **DRUG:** RPV LA
- **OTHER:** Continuous Quality Improvement (CQI) calls

## Key facts

- **NCT ID:** NCT04399551
- **Lead sponsor:** ViiV Healthcare
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-28
- **Primary completion:** 2022-03-07
- **Final completion:** 2023-03-13
- **Target enrollment:** 437 (ACTUAL)
- **Last updated:** 2024-04-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04399551

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04399551, "A Study Evaluating Implementation Strategies for Cabotegravir (CAB)+ Rilpivirine (RPV) Long-acting (LA) Injectables for Human Immunodeficiency Virus (HIV)-1 Treatment in European Countries". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04399551. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*